These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17362999)

  • 1. A mouse model to study tau pathology related with tau phosphorylation and assembly.
    Engel T; Lucas JJ; Hernández F; Avila J
    J Neurol Sci; 2007 Jun; 257(1-2):250-4. PubMed ID: 17362999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits.
    Gómez de Barreda E; Pérez M; Gómez Ramos P; de Cristobal J; Martín-Maestro P; Morán A; Dawson HN; Vitek MP; Lucas JJ; Hernández F; Avila J
    Neurobiol Dis; 2010 Mar; 37(3):622-9. PubMed ID: 20004245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
    Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
    J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippocampal neuronal subpopulations are differentially affected in double transgenic mice overexpressing frontotemporal dementia and parkinsonism linked to chromosome 17 tau and glycogen synthase kinase-3beta.
    Engel T; Goñi-Oliver P; Gomez-Ramos P; Morán MA; Lucas JJ; Avila J; Hernández F
    Neuroscience; 2008 Dec; 157(4):772-80. PubMed ID: 18951953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration.
    Engel T; Lucas JJ; Gómez-Ramos P; Moran MA; Avila J; Hernández F
    Neurobiol Aging; 2006 Sep; 27(9):1258-68. PubMed ID: 16054268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
    Pérez M; Ribe E; Rubio A; Lim F; Morán MA; Ramos PG; Ferrer I; Isla MT; Avila J
    Neuroscience; 2005; 130(2):339-47. PubMed ID: 15664690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau.
    Van der Jeugd A; Hochgräfe K; Ahmed T; Decker JM; Sydow A; Hofmann A; Wu D; Messing L; Balschun D; D'Hooge R; Mandelkow EM
    Acta Neuropathol; 2012 Jun; 123(6):787-805. PubMed ID: 22532069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-γ promotes τ phosphorylation without affecting mature tangles.
    Li A; Ceballos-Diaz C; DiNunno N; Levites Y; Cruz PE; Lewis J; Golde TE; Chakrabarty P
    FASEB J; 2015 Oct; 29(10):4384-98. PubMed ID: 26156074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.
    Rockenstein E; Ubhi K; Mante M; Florio J; Adame A; Winter S; Brandstaetter H; Meier D; Masliah E
    BMC Neurosci; 2015 Nov; 16():85. PubMed ID: 26611895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model.
    Pérez M; Hernández F; Lim F; Díaz-Nido J; Avila J
    J Alzheimers Dis; 2003 Aug; 5(4):301-8. PubMed ID: 14624025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice.
    Stancu IC; Vasconcelos B; Ris L; Wang P; Villers A; Peeraer E; Buist A; Terwel D; Baatsen P; Oyelami T; Pierrot N; Casteels C; Bormans G; Kienlen-Campard P; Octave JN; Moechars D; Dewachter I
    Acta Neuropathol; 2015 Jun; 129(6):875-94. PubMed ID: 25862635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology.
    Leroy K; Ando K; Héraud C; Yilmaz Z; Authelet M; Boeynaems JM; Buée L; De Decker R; Brion JP
    J Alzheimers Dis; 2010; 19(2):705-19. PubMed ID: 20110614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure.
    Rockenstein E; Ubhi K; Trejo M; Mante M; Patrick C; Adame A; Novak P; Jech M; Doppler E; Moessler H; Masliah E
    BMC Neurosci; 2014 Jul; 15():90. PubMed ID: 25047000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
    Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
    Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
    Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
    Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta.
    Kitazawa M; Trinh DN; LaFerla FM
    Ann Neurol; 2008 Jul; 64(1):15-24. PubMed ID: 18318434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo.
    Smith PY; Hernandez-Rapp J; Jolivette F; Lecours C; Bisht K; Goupil C; Dorval V; Parsi S; Morin F; Planel E; Bennett DA; Fernandez-Gomez FJ; Sergeant N; Buée L; Tremblay MÈ; Calon F; Hébert SS
    Hum Mol Genet; 2015 Dec; 24(23):6721-35. PubMed ID: 26362250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of spleen tyrosine kinase and tau phosphorylated at tyrosine 18 in a mouse model of tauopathy and in the human hippocampus.
    Köhler C; Fuhr V; Dinekov M
    Brain Res; 2017 Dec; 1677():1-13. PubMed ID: 28919467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early structural and functional defects in synapses and myelinated axons in stratum lacunosum moleculare in two preclinical models for tauopathy.
    Maurin H; Chong SA; Kraev I; Davies H; Kremer A; Seymour CM; Lechat B; Jaworski T; Borghgraef P; Devijver H; Callewaert G; Stewart MG; Van Leuven F
    PLoS One; 2014; 9(2):e87605. PubMed ID: 24498342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.